WILMINGTON, N.C., (August 1, 2012) - Pharmaceutical Product Development, LLC (PPD) today announced that Lee Babiss, Ph.D., chief scientific officer and executive vice president of global laboratory services, has been named to the 2012 PharmaVOICE 100 list of the most inspiring people in the life sciences industry.
The honor recognizes executives for their ability to influence corporate leadership, research and development, technology, creativity and strategy. PharmaVOICE magazine celebrated Dr. Babiss' conviction and passion for innovation that sustain his ability to develop breakthrough strategies, products and services.
"Considered to be a true innovator, Dr. Lee Babiss is not interested in making small incremental changes, he is challenging himself and his teams to make leaps to find the disruptive technologies and bold solutions that will make a significant impact on how PPD provides services and value to clients and partners and, ultimately, how the company helps bring important medicines to patients," said Taren Grom, editor of PharmaVOICE. "Dr. Babiss' achievements at PPD led to his recent promotion to chief scientific officer and being named to the PharmaVOICE 100."
After more than two decades in the biopharmaceutical industry, Dr. Babiss is helping lead PPD's efforts to innovate contract research organization (CRO) services to support biopharmaceutical partners in delivering life-changing therapies. His ultimate goal is to provide partners with novel solutions that drive program success and bring important medicines to patients.
"To be selected among the 100 industry leaders by PharmaVOICE is rewarding and energizing," Dr. Babiss said. "While this is an individual honor, it is not an individual accomplishment. My colleagues at PPD deserve recognition for their dedication and forward-thinking approach to solving complex problems. At PPD, investing in talented people with extensive R&D expertise and utilizing transformational technologies are keys to meeting the needs of a partnering base that is emphasizing CRO relationships more than ever before."
Prior to joining PPD, Dr. Babiss was president and director of pharmaceutical research for F. Hoffmann-La Roche Ltd., in Basel, Switzerland. Previously, he was vice president of preclinical research and development for Roche, based in Nultey, N.J. At GlaxoWellcome Inc., now GlaxoSmithKline, he held positions of increasing responsibility, including vice president of biological sciences and genetics.
The PharmaVOICE 100 is an annual list of individuals recognized for their positive contributions to the life sciences industry. Honorees are nominated by thousands of PharmaVOICE readers and represent a broad cross section of industry sectors. Those chosen contribute to the growth and well-being of their individual companies, their communities and varied industry associations.
PPD is a leading global contract research organization providing drug discovery, development and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 12,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com.
Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about Dr. Lee Babiss being named to the 2012 PharmaVOICE 100 list, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: the ability to attract, integrate and retain key personnel, including our new chairman and CEO; competition in the outsourcing industry; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; consolidation in the pharmaceutical and biotechnology industries; PPD's ability to win new business; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; risks associated with and dependence on strategic relationships; actual operating performance; the ability to control SG&A spending; risks associated with acquisitions and investments; compliance with drug development regulations; rapid technological advances that make our services less competitive; and changes in the regulation of the drug development process. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD's estimates or views as of any date subsequent to the date hereof.
+1 919 456 5350
+1 910 558 7585